Suggested Topics within your search.
Suggested Topics within your search.
Augmented renal clearance
1
Bevacizumab
1
Biological Products
1
Biosimilar
1
Biotransformation
1
Covalent bonds
1
Critically ill patient
1
Disulphide bond shuffling
1
Disulphide bonds
1
Dosing
1
Drug Industry
1
Drug products
1
Humans
1
IgG1 therapeutics
1
Igg1 therapeutic
1
LC-MS-MS
1
LC-MS/MS
1
Lc.ms/ms
1
Levetiracetam
1
Monte Carlo simulation
1
Neurocritical care
1
Pharmacodynamics
1
Pharmacokinetics
1
Post-translational modifications
1
Protein degradation
1
Protein therapeutics
1
Proteins
1
Sulfur compounds
1
biological product
1
biosimilars
1
-
181
-
182by Navid Neyshaburinezhad, Hengameh Ghasim, Mohammadreza Rouini, Youssef Daali, Yalda H. Ardakani“...) in CYP genes are leading factors of drug pharmacokinetics and toxicity and form pharmacogenetics...”
Published 2021-08-01
Get full text
Article -
183by Anja Kolarič, Maja Kokot, Martina Hrast, Matjaž Weiss, Irena Zdovc, Jurij Trontelj, Simon Žakelj, Marko Anderluh, Nikola MinovskiGet full text
Published 2021-07-01
Article -
184Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapyby Kenji Ikemura, Kenji Ikemura, Shunichi Hiramatsu, Masahiro Okuda, Masahiro Okuda“... transporter 2 (OCT2) associated with pharmacokinetics and/or renal accumulation of various drugs, including...”
Published 2017-12-01
Get full text
Article -
185
-
186
-
187by Markus Vähä-Koskela, Siri Tähtinen, Susanna Grönberg-Vähä-Koskela, Kristian Taipale, Dipongkor Saha, Maiju Merisalo-Soikkeli, Marko Ahonen, Noora Rouvinen-Lagerström, Mari Hirvinen, Ville Veckman, Sampsa Matikainen, Fang Zhao, Päivi Pakarinen, Jarmo Salo, Anna Kanerva, Vincenzo Cerullo, Akseli HemminkiGet full text
Published 2014-01-01
Article -
188by Mengyu Zhang, Soichiro Tajima, Tomohiro Shigematsu, Rao Fu, Hiroshi Noguchi, Keizo Kaku, Akihiro Tsuchimoto, Yasuhiro Okabe, Nobuaki Egashira, Satohiro Masuda“... pharmacokinetics after renal transplantation. Even though CYP3A5 protein is expressed in renal tubular cells...”
Published 2020-04-01
Get full text
Article -
189“... for Biopharmaceutics and Pharmacokinetics, College of Pharmacy, 2Guangdong Province Key Laboratory of Pharmacodynamic...”
Get full text
Article -
190by Paul van den Berg, Wei Gao, Maurice J. Ahsman, Leticia Arrington, Filippos Kesisoglou, Randy Miller, Teun M. Post, Matthew L. Rizk“... and extrinsic factors on pharmacokinetics and pharmacodynamics, a model‐informed drug development (MIDD...”
Published 2021-07-01
Get full text
Article -
191
-
192
-
193“... nanoparticles and the effect of PEGylation on oral absorption of fenofibrate (FN), a Biopharmaceutics...”
Get full text
Article -
194
-
195by Ilze Bot, Natalia V. Ortiz Zacarías, Wilhelmus E. A. de Witte, Henk de Vries, Peter J. van Santbrink, Daniël van der Velden, Mara J. Kröner, Dirk-Jan van der Berg, Dean Stamos, Elizabeth C. M. de Lange, Johan Kuiper, Adriaan P. IJzerman, Laura H. Heitman“... artery and the aortic root. We then showed that the long pharmacokinetic half-life of 15a combined...”
Published 2017-03-01
Get full text
Article -
196“... Ishida1 1Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences...”
Get full text
Article -
197“... to safely and economically treat hepatopathy. However, OA, a Biopharmaceutics Classification System IV...”
Get full text
Article -
198
-
199by Anna K. Krome, Tim Becker, Stefan Kehraus, Andrea Schiefer, Christian Steinebach, Tilman Aden, Stefan J. Frohberger, Álvaro López Mármol, Dnyaneshwar Kapote, Rolf Jansen, Lillibeth Chaverra-Muñoz, Marc P. Hübner, Kenneth Pfarr, Thomas Hesterkamp, Marc Stadler, Michael Gütschow, Gabriele M. König, Achim Hoerauf, Karl G. Wagner“...) properties were analyzed. Pharmacokinetic evaluations after intravenous and oral administration were...”
Published 2020-11-01
Get full text
Article -
200